Pfizer Successfully Completes Tender Offer for Shares of Encysive Pharmaceuticals Inc.
- Details
- Category: Pfizer
Pfizer Inc (NYSE:PFE) announced that Explorer Acquisition Corp., a wholly-owned subsidiary of Pfizer, has purchased all of the shares validly tendered and not withdrawn pursuant to its tender offer for all of the outstanding shares of common stock of Encysive Pharmaceuticals Inc. (NASDAQ: ENCY) at a purchase price of $2.35 per share, net to the seller in cash, without interest thereon and less any required withholding taxes.
Rasilez® reduces left ventricular hypertrophy, a powerful predictor of heart disease
- Details
- Category: Novartis
Rasilez® (aliskiren), the first-in-class direct renin inhibitor, has shown clinically meaningful reductions in left ventricular hypertrophy, a proven predictor of heart disease, that are comparable to those seen with the current standard-of-care treatment[1].
Bayer appeals invalidity ruling on its Yasmin® Patent
- Details
- Category: Bayer
Bayer filed a Notice of Appeal in the United States District Court for the District of New Jersey. Bayer is appealing from a March 3, 2008 opinion and order in which District Judge Peter G. Sheridan held that certain patent claims of Bayer Schering's U.S. Patent No. 6,787,531 for the company's oral contraceptive Yasmin (drospirenone 3 mg and ethinyl estradiol 0.03mg) were invalid because they would have been obvious to the person of ordinary skill in the art.
Crestor Outcomes Study JUPITER Closes Early Due To Unequivocal Evidence Of Benefit
- Details
- Category: AstraZeneca
AstraZeneca today announced it has decided to stop the CRESTOR JUPITER clinical study early based on a recommendation from an Independent Data Monitoring Board and the JUPITER Steering Committee, which met on March 29, 2008. The study will be stopped early because there is unequivocal evidence of a reduction in cardiovascular morbidity and mortality amongst patients who received CRESTOR when compared to placebo.
Novel oral anticoagulant Pradaxa® (dabigatran etexilate) approved by the European Commission
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim announced that the European Commission has granted marketing authorisation of the novel, oral direct thrombin inhibitor, Pradaxa® (dabigatran etexilate) in all 27 EU member states. It is anticipated that Pradaxa® will be launched in Germany and the United Kingdom in the coming weeks.
Levitra® - Therapy suitable for men with High Cholesterol
- Details
- Category: Bayer
At the 23rd Annual European Association of Urology (EAU) Congress, results were presented which added evidence that Levitra® (vardenafil HCI) works very well in men with dyslipidemia.[1] The double-blind, placebo-controlled trial in about 400 men showed that Levitra® significantly improved the ability of men with erectile dysfunction (ED) and high cholesterol, to achieve and maintain an erection for successful sexual intercourse.[2]
Aurobindo Pharma expands in Europe
- Details
- Category: Business
Aurobindo Pharma announced that it has recently concluded a strategic deal, for acquisition of Intellectual Property & Marketing Authorizations, with TAD Italy, a generic company registered in Italy. This acquisition will give Aurobindo an access to more than 70 ready to market products which will fast track Aurobindo's entry into the Italian generic market.
More Pharma News ...
- GSK charitable support valued at £282 million in 2007
- Federal Court of Appeal in Canada Upholds Lipitor Enantiomer Patent
- Zevalin® Receives Positive CHMP Opinion in Europe for First-Line Consolidation Treatment
- Genzyme Withdraws Bioenvision's European Filing of Evoltra® in Elderly AML Patients
- GSK statement on MHRA investigation
- First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
- Trial Date Set For SEROQUEL® Patent Litigation